Finerenone Oral Tablet

Phase 2

BAYER (BAYRY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q1 '27

BAYRYPhase 2$42.5B

Finerenone Oral Tablet Phase 2 Est. Readout

Finerenone Oral Tablet• Kidney Transplant; Complications100

Q1 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Kidney Transplant; Complications

View Full Landscape

Drug Information

Target Indication

Kidney Transplant; Complications

Clinical Trial

NCT06059664

Last updated: 8/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Oxybutynin (Oxytrol, BAY839380)Phase 3

Overactive Bladder

Amikacin Inhalation Solution (BAY41-6551)Phase 3

Pneumonia, Bacterial

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

Regorafenib (Stivarga, BAY73- 4506)Phase 3

Colorectal Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts